Molecular targets of the antiinflammatory Harpagophytum procumbens (Devil's claw): Inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1

Phytotherapy Research

Volumn 26, Issue 6, 2012, Pages 806-811

  Fiebich, Bernd L ^a,b   Muñoz, Eduardo ^c   Rose, Thorsten ^b   Weiss, Gabriele ^d   McGregor, Gerard P ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b VIVACELL BIOTECHNOLOGY GMBH   (Germany)

^c VivaCell Biotechnology España SL ^*  (Spain)

^d Pascoe Pharmazeutische Praeparate GmbH Giessen   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

cytokines; Nuclear factor B; phytomedicine; rheumatic arthritis; signal transduction

Indexed keywords

ALCOHOL; CYCLOOXYGENASE 2; HARPAGOPHYTUM PROCUMBENS EXTRACT; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PASCOE; PROSTAGLANDIN E2; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; MEDIATOR RELEASE; MONOCYTE; PROMOTER REGION; PROTEIN CONTENT; PROTEIN DNA BINDING; PROTEIN TARGETING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG EVALUATION, PRECLINICAL; ETHANOL; GENES, REPORTER; HARPAGOPHYTUM; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MICE; MONOCYTES; NF-KAPPA B; PLANT EXTRACTS; PROTEIN BINDING; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

HARPAGOPHYTUM PROCUMBENS;

EID: 84861804712     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3636     Document Type: Article

References (30)

1. Brendler T, Gruenwald J, Ulbricht C, Basch E,. 2006. Devil's claw (Harpagophytum procumbens DC): an evidence-based systematic review by the Natural Standard Research Collaboration. J Herb Pharmacother 6: 89-126.
2. Brien S, Lewith GT, McGregor G,. 2006. Devil's claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. J Altern Complement Med 12: 981-993.
3. Calzado MA, Bacher S, Schmitz ML,. 2007. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 14: 367-376.
4. Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B,. 2000. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 7: 177-183.
5. Chomczynski P, Sacchi N,. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Ann Biochem 162: 156-157.
6. Chrubasik S, Conradt C, Black A,. 2003. The quality of clinical trials with Harpagophytum procumbens. Phytomedicine 10: 613-623.
7. Chrubasik S, Conradt C, Roufogalis BD,. 2004. Effectiveness of Harpagophytum extracts and clinical efficacy. Phytother Res 18: 187-189.
8. Chrubasik S, Junck H, Breitschwerdt H, Conradt C, Zappe H,. 1999. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind study. Eur J Anaesthesiol 16: 118-129.
9. Chrubasik S, Thanner J, Kunzel O, Conradt C, Black A, Pollak S,. 2002. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 9: 181-194.
10. Denner SS,. 2007. A review of the efficacy and safety of devil's claw for pain associated with degenerative musculoskeletal diseases, rheumatoid, and osteoarthritis. Holist Nurs Pract 21: 203-207.
11. EMEA. 2008. Committee on Herbal Medicinal Products. (208) Community Herbal Monograph on Harpagophytum procumbens DC. and/or Harpagophytum zeyheri Decne, radix (EMEA/HMPC/251323/2006), adopted Nov. 2008.
12. English D, Andersen BR,. 1974. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 5: 249-252.
13. Fiebich BL, Heinrich M, Hiller KO, Kammerer N,. 2000. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine 8: 28-30.
14. Gagnier JJ, van Tulder MW, Berman B, Bombardier C,. 2007. Herbal medicine for low back pain: a Cochrane review. Spine (Phila Pa 1976)) 32: 82-92.
15. kappa B activation. J Ethnopharmacol 104: 149-155.
16. Inaba K, Murata K, Naruto S, Matsuda H,. 2010. Inhibitory effects of devil's claw (secondary root of Harpagophytum procumbens) extract and harpagoside on cytokine production in mouse macrophages. J Nat Med 64: 219-222.
17. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M,. 2000. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275: 23627-23635.
18. Jang MH, Lim S, Han SM, et al,. 2003. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. J Pharmacol Sci 93: 367-371.
19. Kundu JK, Mossanda KS, Na HK, Surh YJ,. 2005. Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC. on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets. Cancer Lett 218: 21-31.
20. LaemmLi UK,. 1970. Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 227: 680-685.
21. Loew D, Rietbrock N,. 1996. Harpagophytum procumbens: Wirkung von Extrakten auf die Eicosanoidbiosynthese in Ionophor A23187-stimuliertem menschlichem Vollblut. In Phytopharmaka II: Forschung und klinische Anwendung. Steinkopff Verlag: Darmstadt, 95-100.
22. Noble PB, Cutts JH, Carroll KK,. 1968. Ficoll flotation for the separation of blood leukocyte types. Blood 31: 66-73.
23. Reimold AM,. 2002. TNFalpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 1: 377-392.
24. Ruetten S, Kuhn M,. 2005. Spezialextrakt aus Teufelskrallenwurzel: Klinische Vergleichsstudie bei Patienten mit unspezifischen Schmerzen im Lumbalbereich. Îrztezeitschrift für Naturheilverfahren 46: 114-116.
25. kappaB, NFAT, and activator protein 1 signaling pathways. J Immunol 172: 2341-2351.
26. Schulze-Tanzil G, Hansen C, Shakibaei M,. 2004. [ Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro ]. Arzneimittelforschung 54: 213-220.
27. Warnock M, McBean D, Suter A, Tan J, Whittaker P,. 2007. Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders. Phytother Res 21: 1228-1233.
28. Wegener T, Lupke NP,. 2003. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytother Res 17: 1165-1172.
29. Westacott CI, Sharif M,. 1996. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 25: 254-272.
30. Widomski D, Fretland DJ, Gasiecki AF, Collins PW,. 1997. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacol Immunotoxicol 19: 165-174.